Breast Cancer: Lifestyle Factors Linked to 25% of Healthy Years Lost | Global Cases to Rise

More than a quarter of healthy years lost to breast cancer globally are linked to modifiable lifestyle factors – including diet and smoking – according to the most comprehensive analysis of its kind, published in The Lancet Oncology. The study, drawing on data spanning three decades and over 200 countries, underscores the significant impact of preventable risk factors on the burden of this disease, even as overall cases are projected to rise sharply in the coming decades.

Researchers from the Global Burden of Disease Study Breast Cancer Collaborators analyzed data from 1990 to 2023, forecasting trends up to 2050. Their findings indicate that new breast cancer cases in women are predicted to increase by a third globally, rising from 2.3 million in 2023 to over 3.5 million in 2050. In the UK, approximately one in seven women will develop breast cancer during their lifetime. While advancements in screening and treatment have improved outcomes in high-income countries, the increasing burden of the disease is shifting towards low- and lower-middle-income countries, where diagnosis often occurs at later stages and access to quality care is limited.

Lifestyle Factors and Years of Healthy Life Lost

The analysis pinpointed specific lifestyle factors contributing to the loss of healthy years. High red meat consumption emerged as the most significant modifiable risk factor, linked to nearly 11% of all healthy life lost due to breast cancer. Tobacco use, including exposure to secondhand smoke, accounted for 8%, while high blood sugar contributed to 6%. Other factors included a high body mass index (4%), high alcohol use, and low physical activity (both 2%). These findings align with previous research from Cancer Research UK, which estimated that over four in ten UK cancer cases are preventable through lifestyle changes. The Lancet study provides a global perspective on these well-established links.

Shifting Age Demographics and Rising Incidence

Globally, in 2023, three times as many new breast cancer cases were diagnosed in women aged 55 or older compared to those aged 20-54 (161 cases per 100,000 women versus 50). However, the study revealed a concerning trend: the rate of new cases in younger women (20-54) has increased by nearly a third (29%) since 1990, while rates in older women have remained relatively stable. This rise in incidence among younger women warrants further investigation to understand the underlying causes.

Understanding the Study’s Methodology and Limitations

The Global Burden of Disease Study is a large-scale, collaborative effort that utilizes data from population-based cancer registries and other sources to estimate the incidence, mortality, and risk factors for various diseases. The study’s strength lies in its comprehensive scope and the extensive data it incorporates. However, it’s important to acknowledge its limitations. The analysis relies on available data, which may vary in quality and completeness across different countries. Establishing a causal link between lifestyle factors and breast cancer risk is complex, as many other factors – including genetics, hormonal influences, and environmental exposures – too play a role. The study identifies associations, but does not prove that changing these lifestyle factors will definitively prevent breast cancer.

What Does This Indicate for Individuals?

The findings reinforce the importance of adopting a healthy lifestyle as a proactive step towards reducing breast cancer risk. This includes maintaining a healthy weight, engaging in regular physical activity, limiting red meat consumption, avoiding tobacco use, and moderating alcohol intake. These recommendations are consistent with broader guidelines for overall health and well-being. It’s crucial to remember that these are population-level recommendations, and individual risk factors may vary. Individuals with concerns about their breast cancer risk should consult with a qualified healthcare professional for personalized advice and screening recommendations. The University of Cambridge highlights that 15,000 women a year could benefit from whole genome sequencing.

The Role of Whole Genome Sequencing

Recent advancements in genomic research, including whole-genome sequencing, are offering new avenues for understanding breast cancer risk and tailoring treatment strategies. Whole-genome sequencing involves mapping the entire genetic code of an individual, providing a comprehensive picture of their genetic predispositions. This information can help identify individuals at higher risk of developing breast cancer and guide decisions about screening and preventive measures. Genomic data can inform treatment choices by identifying specific genetic mutations that may make a tumor more or less responsive to certain therapies. However, the clinical application of whole-genome sequencing in breast cancer is still evolving, and further research is needed to determine its optimal use and cost-effectiveness. The ASCO Post reports on the clinical usefulness of linking whole-genome data to mortality statistics.

Looking Ahead: Global Collaboration and Continued Research

Claire Rowney, chief executive of Breast Cancer Now, emphasized the need for global collaboration to address the growing burden of breast cancer. The organization is actively working to build partnerships with researchers and funders worldwide to accelerate progress towards its ambitious goal of ensuring that everyone with breast cancer can live and live well by 2050. Continued research is essential to deepen our understanding of the complex interplay of genetic, lifestyle, and environmental factors that contribute to breast cancer risk, and to develop more effective prevention and treatment strategies. Public health initiatives aimed at promoting healthy lifestyles and increasing access to early detection and quality care will also be crucial in reducing the impact of this disease.

What’s next? Ongoing surveillance of breast cancer incidence and mortality rates, coupled with continued research into risk factors and treatment options, will be vital for informing public health strategies and improving outcomes for women worldwide. Regular reviews of clinical guidelines and screening recommendations will ensure that they are based on the latest evidence. Efforts to address health disparities and improve access to care in low- and lower-middle-income countries are essential to reducing the global burden of breast cancer.